Genor Biopharma Holdings (HKG:6998) proposed to remove its auditor PricewaterhouseCoopers due to disagreements over audit documentation and financial reporting period for publishing results, according to a Tuesday filing with the Hong Kong bourse.
The company also proposed the appointment of Ernst & Young as the new auditor, subject to shareholder approval at an upcoming extraordinary general meeting on Feb. 19.
The pharmaceutical company's shares were almost 2% higher in recent trading.